隨著新型冠狀病毒肺炎符合出院標(biāo)準(zhǔn)的患者逐日增多，恢復(fù)期的中醫(yī)治療應(yīng)受到關(guān)注，國家衛(wèi)生健康委員會及地方推出的診療方案中都加入了恢復(fù)期的中醫(yī)辨證分型及治療方藥。查閱文獻，并分析新冠肺炎恢復(fù)期的臨床特征及中醫(yī)分型，發(fā)現(xiàn)氣陰兩虛證為恢復(fù)期的主要證候，生脈散為氣陰兩虛證的代表方劑。對生脈散用于氣陰兩虛證疾病的臨床應(yīng)用及其抗肺纖維化和血管內(nèi)皮細胞損傷的藥理作用進行了綜述，對其用于新冠肺炎恢復(fù)期的可行性進行探討，以期為臨床醫(yī)生和患者的恢復(fù)期中醫(yī)治療提供參考。

As the number of discharged patients with novel coronavirus pneumonia (COVID-19) increased, TCM treatment received more attention. Some COVID-19 diagnosis and treatment plans issued by national health commission and local government recorded the syndrome differentiation and classification of TCM in the convalescent period and the treatment prescriptions. The clinical characteristics and TCM classification of convalescent period were also reported in recent literatures. Deficiency of Qi and Yin is the main syndrome in recovery period, and the Shengmai Powder (SMS) is the representative prescription. This paper reviews the studies of SMS in the treatment of deficiency of Qi and Yin, pulmonary fibrosis and vascular endothelial cell injury. The feasibility of SMS for the discharged patients with COVID-19 was discussed. This review will provide reference for clinical doctors and patients in the recovery period of TCM treatment.

R259;R285.6

國家科技重大專項“中醫(yī)藥優(yōu)勢領(lǐng)域的創(chuàng)新中藥關(guān)鍵技術(shù)開發(fā)研究”（2017ZX09301005）